RhyGaze, a Basel, Switzerland- and Philadelphia, PA-based biotechnology company developing gene therapies for retinal diseases, raised USD 86M in Series A funding.
The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund.
The company intends to use the funds for further development of its lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness.
Founded by Drs. Botond Roska, Bence Gyƶrgy and Charles Gubser and led by CEO Dr. Katherine High, RhyGaze is a biotechnology company focused on developing gene therapies for retinal diseases causing blindness. Founded on the research from the Institute of Molecular and Clinical Ophthalmology Basel (IOB), the copamny aims to restore vision and transform the lives of patients worldwide. IOB scientists.
The name RhyGaze derives from the Basel-German word for the Rhein (Rhy), on the banks of which the IOB is located.
FinSMEs
13/01/2025